Bacterial Spectrum of Activity of Cefuroxime
Introduction to Cefuroxime's Spectrum
- Cefuroxime demonstrates broad-spectrum activity against common respiratory pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, and most Enterobacteriaceae, though it has limited activity against drug-resistant S. pneumoniae and no activity against Pseudomonas aeruginosa, enterococci, or anaerobes like Bacteroides fragilis 1, 2
Gram-Positive Coverage
- Cefuroxime axetil has activity against S. pneumoniae similar to cefpodoxime and cefdinir, achieving approximately 75-85% coverage based on pharmacokinetic/pharmacodynamic breakpoints 3, 4
Gram-Negative Coverage
- Haemophilus influenzae: Cefuroxime axetil achieves 70-85% coverage based on PK/PD breakpoints, though it is less active than cefpodoxime 1, 2, 4
- Moraxella catarrhalis: Approximately 50% coverage, significantly lower than third-generation cephalosporins or fluoroquinolones 4
Clinical Context and Limitations
- Cefuroxime has no clinically significant activity against drug-resistant S. pneumoniae (DRSP), which is a major consideration when selecting empiric therapy for respiratory infections 1, 2
- Among oral cephalosporins for respiratory pathogens, cefuroxime axetil ranks in the middle tier—superior to cefaclor and loracarbef but inferior to cefpodoxime proxetil for H. influenzae coverage 1, 2, 5
- For S. pneumoniae, it achieves similar activity to cefdinir and cefprozil 2, 5
Cephalosporin Therapy Guidelines
Introduction to Cephalosporin Selection
- Cefuroxime is superior to cefadroxil for most clinical infections due to its broader spectrum of activity, particularly against beta-lactamase-producing organisms and respiratory pathogens 6
Antimicrobial Spectrum and Guideline Recommendations
- The French and European guidelines recommend cefuroxime as first-line therapy for acute sinusitis, alongside amoxicillin-clavulanate and third-generation cephalosporins, with no mention of cefadroxil 6
- Cefuroxime is specifically recommended for maxillary, frontal, fronto-ethmoidal, and sphenoidal sinusitis with proven 5-day efficacy 6